Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 14, 2025
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 14, 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from …
Rising Chronic Illnesses and Growing Focus on Physical Wellness Drive Physiotherapy Equipment Market Growth
EIN Presswire
·
May 14, 2025
The rising prevalence of chronic illnesses is one of the main drivers of the physiotherapy equipment market's expansion. VANCOUVER, BRITISH COLUMBIA, CANADA, May 14, 2025 /EINPresswire.com/ -- The global Physiotherapy Equipment market size is expected …
Precipio Announces its Q1-2025 Financial Results
GlobeNewswire
·
May 14, 2025
NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain …
Kaleido Life Introduces the Third Way to Fund Your Future: Cash. Credit. Kaleido.
GlobeNewswire
·
May 14, 2025
Photo Courtesy of Craig Du Bruyn ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Forget cash or credit. Kaleido Life is pioneering a third way to fund your life—by inheriting from your future self, today. Currently in pre-launch, Kaleido Life is an Atlanta-based …
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting …
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
GlobeNewswire
·
May 14, 2025
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: …
Radical Truths Summit to Address Global Trends in Surveillance, Psychological Manipulation, and Public Autonomy
EIN Presswire
·
May 14, 2025
Virtual event to feature international experts, researchers, and targeted survivors May 21 – June 3, 2025 NA, TX, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- From concerns over digital privacy to the rise in reported psychological coercion and …
SS Innovations Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “ …
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewswire
·
May 14, 2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the lives of …
Jasper Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
GlobeNewswire
·
May 14, 2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using …
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean …
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using …
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
GlobeNewswire
·
May 14, 2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the …
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and …
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in …
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
GlobeNewswire
·
May 14, 2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in …
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 14, 2025
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN …